BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
PA accuses Israel of 'human trafficking' after planeload of Gazans arrives in South Africa - 2Rights groups condemn Israel Police decision to ban Sudan Genocide protests nationwide
- 3Europe pledges over €15bn for clean energy for Africa
- 4The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with
- 5Extraordinary Guinness World Records That Will Astound You
- Journey Lines for Each Explorer: Track down Your Ideal Journey
- Which Film Has the Incomparable Melodic Score?
- The Way to Monetary Health: Individual budget Change
- The Most Vital Crossroads in Olympic History
- Top Smoothie Flavor: What's Your Mix?
- Thousands of genomes reveal the wild wolf genes in most dogs’ DNA
- The Effect of Online Organizations on Society: Beating the Difficulties
- Figure out How to Explore the Infotainment Framework in the Slam 1500.
- The most effective method to Recognize an Excellent Lab Precious stone
